Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP1A2 | P05177 | 1/20 | 0.59 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.59 |
| ▸ | HTT | P42858 | 4/20 | 0.54 |
| ▸ | SMN1; SMN2 | Q16637 | 3/20 | 0.50 |
| ▸ | LMNA | P02545 | 3/20 | 0.49 |
| ▸ | POLB | P06746 | 1/20 | 0.49 |
| ▸ | GAA | P10253 | 1/20 | 0.47 |
| ▸ | CNR2 | P34972 | 1/20 | 0.46 |
| ▸ | HPGD | P15428 | 1/20 | 0.46 |
| ▸ | MEN1 | O00255 | 2/20 | 0.44 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.44 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.44 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.43 |
| ▸ | MAPT | P10636 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1357879 | 0.82 | HTT (0.50) | CYP1A2CYP2C19HTTSMN1; SMN2LMNA | |
| SCHEMBL16177307 | 0.81 | SMN1; SMN2 (0.51) | CYP1A2CYP2C19HTTSMN1; SMN2LMNA | |
| SCHEMBL21807935 | 0.81 | CYP1A2 (0.46) | CYP1A2CYP2C19HTTSMN1; SMN2LMNA | |
| SCHEMBL38658679 | 0.80 | CYP1A2 (0.45) | CYP1A2CYP2C19HTTSMN1; SMN2LMNA | |
| SCHEMBL2215634 | 0.79 | CNR2 (0.47) | CYP1A2CYP2C19HTTGAACNR2 | |
| SCHEMBL31719625 | 0.79 | CNR2 (0.47) | CYP1A2CYP2C19HTTLMNAPOLB | |
| SCHEMBL28965242 | 0.79 | CYP1A2 (0.50) | CYP1A2CYP2C19HTTGAACNR2 | |
| SCHEMBL24553896 | 0.79 | HTT (0.50) | CYP1A2CYP2C19HTTSMN1; SMN2LMNA | |
| SCHEMBL24485098 | 0.78 | ALDH1A1 (0.56) | CYP1A2HTTSMN1; SMN2LMNAGAA | |
| SCHEMBL1876572 | 0.78 | CNR2 (0.46) | CYP1A2CYP2C19HTTGAACNR2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 97 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-112939829-B | Synthetic method of aryl trifluoromethyl thioether | 武汉药明康德新药开发有限公司 | 2023-02-21 | — | — | CN | claimed |
| CN-112939829-A | Synthetic method of aryl trifluoromethyl thioether | 武汉药明康德新药开发有限公司 | 2021-06-11 | — | — | CN | claimed |
| US-12454530-B2 | Amido cyclohexane acid derivatives as LPA receptor inhibitors | CHIESI FARMACEUTICI S.P.A. (IT) | 2025-10-28 | — | — | US | disclosed |
| US-20250163022-A1 | PARP1 INHIBITORS | SYNNOVATION THERAPEUTICS, INC. | 2025-05-22 | — | — | US | disclosed |
| EP-4554680-A1 | INHIBITORS OF HPK1 AND METHODS OF USE THEREOF | Arcus Biosciences, Inc. (US) | 2025-05-21 | — | — | EP | disclosed |
| WO-2025096751-A1 | MACROCYCLIC INHIBITORS OF ATP CITRATE LYASE | ESPERION THERAPEUTICS, INC. (US) | 2025-05-08 | — | — | WO | disclosed |
| US-12258354-B2 | AhR modulators | IDEAYA BIOSCIENCES, INC. (US) | 2025-03-25 | — | — | US | disclosed |
| US-20250066341-A1 | CYCLOHEXANE ACID DERIVATIVES AS LPA RECEPTOR INHIBITORS | CHIESI FARMACEUTICI S.P.A. (IT) | 2025-02-27 | — | — | US | disclosed |
| WO-2025026266-A1 | COMPOUND AS LPAR1 ANTAGONIST, PHARMACEUTICAL COMPOSITION THEREOF AND USE THEREOF | 武汉朗来科技发展有限公司 | 2025-02-06 | — | — | WO | disclosed |
| EP-4452963-A1 | PARP1 INHIBITORS | Synnovation Therapeutics, Inc. (US) | 2024-10-30 | — | — | EP | disclosed |
| EP-4452965-A1 | CYCLOHEXANE ACID DERIVATIVES AS LPA RECEPTOR INHIBITORS | Chiesi Farmaceutici S.p.A. (IT) | 2024-10-30 | — | — | EP | disclosed |
| US-8980888-B2 | Pyrazole derivative | MOCHIDA PHARMACEUTICAL CO., LTD. (JP) | 2015-03-17 | — | — | US | disclosed |
| US-8980889-B2 | Pyrazole derivative | MOCHIDA PHARMACEUTICAL CO., LTD. (JP) | 2015-03-17 | — | — | US | disclosed |
| US-20150005232-A1 | INDAZOLE DERIVATIVES | TAKEDA PHARMACEUTICAL COMPANY LIMITED (US) | 2015-01-01 | — | — | US | disclosed |
| US-20140378447-A1 | NOVEL PYRAZOLE DERIVATIVE | MOCHIDA PHARMACEUTICAL CO., LTD. (JP) | 2014-12-25 | — | — | US | disclosed |
| US-20140378448-A1 | NOVEL PYRAZOLE DERIVATIVE | MOCHIDA PHARMACEUTICAL CO., LTD. (JP) | 2014-12-25 | — | — | US | disclosed |
| WO-2013189862-A1 | SUBSTITUTED PYRAZOLE COMPOUNDS AS LPAR ANTAGONISTS | F. HOFFMANN-LA ROCHE AG (CH) | 2013-12-27 | — | — | WO | disclosed |
| WO-2013130855-A1 | INDAZOLE DERIVATIVES | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2013-09-06 | — | — | WO | disclosed |
| US-7417063-B2 | Bicyclic heterocycles useful as serine protease inhibitors | BRISTOL-MYERS SQUIBB COMPANY (US) | 2008-08-26 | — | — | US | disclosed |
| US-20050228000-A1 | of the coagulation cascade or contact activation system: thrombin, factor Xa, factor XIa, factor IXa, factor VIIa or plasma kallikrein; e.g. -(6-carbamimidoyl-1H-indol-3-ylmethyl)-4-methoxy-biphenyl-2-carboxylic acid; anticoagulant, antiinflammatory agent | BRISTOL-MYERS SQUIBB COMPANY | 2005-10-13 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (8 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-12454530-B2 | Amido cyclohexane acid derivatives as LPA receptor inhibitors | LPAR1, LPAR2, LPAR3 | CYP1A2 1880/4885CYP2C19 3916/4885HTT 4372/4885 |
| US-20150005232-A1 | INDAZOLE DERIVATIVES | GPR119, INSR, INSRR | CYP1A2 6/4885CYP2C19 12/4885HTT 1121/4885 |
| US-20050228000-A1 | of the coagulation cascade or contact activation system: thrombin, factor Xa, factor XIa, factor IXa, factor VIIa or plasma kallikrein; e.g. -(6-carbamimidoyl-1H-indol-3-ylmethyl)-4-methoxy-biphenyl-2-carboxylic acid; anticoagulant, antiinflammatory agent | F12, F11, F2 | CYP1A2 910/4885CYP2C19 790/4885HTT 4703/4885 |
| US-12258354-B2 | AhR modulators | AHR, ARNT, RORB | CYP1A2 39/4885CYP2C19 347/4885HTT 387/4885 |
| US-20250163022-A1 | PARP1 INHIBITORS | PARP1, PARP11, PARP12 | CYP1A2 4164/4885CYP2C19 3920/4885HTT 1131/4885 |
| US-20140378447-A1 | NOVEL PYRAZOLE DERIVATIVE | PDE10A, PDE3A, PDE5A | CYP1A2 322/4885CYP2C19 134/4885HTT 1143/4885 |
| US-20140378448-A1 | NOVEL PYRAZOLE DERIVATIVE | PDE10A, PDE3A, PDE5A | CYP1A2 322/4885CYP2C19 134/4885HTT 1143/4885 |
| US-20250066341-A1 | CYCLOHEXANE ACID DERIVATIVES AS LPA RECEPTOR INHIBITORS | LPAR1, LPAR2, LPAR3 | CYP1A2 1448/4885CYP2C19 3844/4885HTT 4198/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.